Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Pfizer's pain drug

Pfizer has announced that the US Food and Drug Administration has approved its drug Oxecta for use in the management of acute and chronic moderate to severe pain

Pfizer has announced that the US Food and Drug Administration (FDA) has approved its drug Oxecta (oxycodone) for use in the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

Oxecta makes use of a technology that is designed to discourage methods of drug tampering associated with abuse of opioids. Pfizer has licensed the technology from Acura, a pharma company specialising in developing product candidates to potentially deter abuse and misuse.

Opioid analgesics such as Oxecta are prescribed for patients whose condition isn't managed by other pain treatments, but can result in overdose and death if abused.

Speaking on the approval, Olivier Brandicourt, Pfizer president and general manager, Primary Care, said: "We recognise our responsibility to physicians and patients and remain committed to appropriate access to pain treatment and developing medicines to potentially address this important public health and safety issue."

Oxecta was originally developed by King Pharmaceuticals. Pfizer acquired the drug when it purchased King in late 2010.

21st June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
fox&cat

up to your ears in it? some pressure is helpful but too much of the wrong sort quickly takes its...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....